Longeveron获得美国针对年龄缺陷的干细胞疗法专利,等待批准。 Longeveron gets U.S. patent for stem cell therapy targeting age-related frailty, pending approval.

Longeveron公司获得了美国对其干细胞疗法的专利Laromestrocel, 用于治疗与慢性炎症(称为炎症)有关的与老龄化有关的脆弱弱点。 Longeveron Inc. has received a U.S. patent for its stem cell therapy, laromestrocel, to treat aging-related frailty linked to chronic inflammation, known as inflammaging. 该专利有效期至2038年,并可能延长有效期,涵盖使用年轻捐赠者提供的异基因中子细胞干细胞,以改善老年人的身体功能和行走能力。 The patent, valid until 2038 with possible extension, covers the use of allogeneic mesenchymal stem cells from young donors to improve physical function and walking ability in older adults. 早期临床试验显示出积极结果,但治疗仍属调查性质,尚未获准供公众使用。 Early clinical trials show positive results, but the therapy remains investigational and not yet approved for public use. 该公司还在开发儿科心脏病和阿尔茨海默氏病的治疗方法,并得到了林业发展局的指定。 The company is also developing the treatment for pediatric heart conditions and Alzheimer’s disease, supported by FDA designations.